Chinese General Practice ›› 2022, Vol. 25 ›› Issue (21): 2597-2604.DOI: 10.12114/j.issn.1007-9572.2022.0108
Special Issue: 心肌梗死最新文章合集; 心血管最新文章合集
• Original Research • Previous Articles Next Articles
Received:
2022-02-10
Revised:
2022-03-20
Published:
2022-07-20
Online:
2022-04-28
Contact:
Xiaoyan ZHAO
About author:
通讯作者:
赵晓燕
作者简介:
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2022.0108
组别 | 例数 | 男性〔n( %)〕 | 年龄( | IABP后心搏骤停〔n( %)〕 | AMI类型〔n(%)〕 | 吸烟史〔n( %)〕 | 高血压史〔n( %)〕 | 高脂血症史〔n(%)〕 | 糖尿病史〔n( %)〕 | 中度以上肾功能不全史〔n(%)〕 | 心肌梗死史〔n(%)〕 | 脑卒中史〔n( %)〕 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
STEMI | NSTEMI | ||||||||||||
IABP组 | 65 | 35(53.8) | 64.9±11.3 | 11(16.9) | 51(78.5) | 14(21.5) | 18(27.7) | 29(44.6) | 7(10.8) | 26(40.0) | 24(36.9) | 9(13.8) | 15(23.1) |
IABP+ECMO组 | 26 | 16(61.5) | 57.2±14.0 | 15(57.7) | 22(84.6) | 4(15.4) | 12(46.2) | 11(42.3) | 2(7.7) | 8(30.8) | 11(42.3) | 3(11.5) | 4(15.4) |
检验统计量值 | 0.466a | -2.713b | 15.125a | 0.443a | 0.443a | 2.864a | 0.040a | 0.197a | 0.676a | 0.228a | 0.086a | 0.665a | |
P值 | 0.504 | 0.008 | <0.001 | 0.506 | 0.506 | 0.091 | 0.841 | 0.657 | 0.411 | 0.633 | 0.769 | 0.415 | |
组别 | IABP上机前LVEF( | 首次血糖〔M(P25,P75),mmol/l〕 | ALT〔M(P25,P75),u/l〕 | Scr〔M(P25,P75),μmmol/l〕 | 估算肾小球滤过率〔M(P25,P75),%〕 | 糖化血红蛋白〔M(P25,P75),%〕 | NT-proBNP〔M(P25,P75),ng/L〕 | IABP-SHOCKII评分〔M(P25,P75),分〕 | |||||
IABP组 | 42.12±11.73 | 13.10(9.20,17.15) | 91.00(35.50,239.50) | 104.00(72.50,136.85) | 67.94(42.81,94.80) | 6.10(5.70,7.67) | 5 118.00(2 415.50,9 406.00) | 2.00(1.00,3.00) | |||||
IABP+ECMO组 | 42.43±9.13 | 13.95(10.48,18.08) | 99.50(44.00,222.25) | 104.00(87.53,166.05) | 71.29(44.69,93.23) | 6.20(5.78,7.13) | 3 821.50(1 940.00,14 337.30) | 3.00(2.00,3.30) | |||||
检验统计量值 | -0.137b | -0.514 | -0.624 | -1.147 | -0.079b | -0.281 | -0.325 | -0.939 | |||||
P值 | 0.891 | 0.607 | 0.533 | 0.252 | 0.937 | 0.778 | 0.745 | 0.348 | |||||
组别 | IABP-SHOCKⅡ评分〔n(%)〕 | VIS〔M(P25,P75),分〕 | 手术入路〔n(%)〕 | 病变血管数量〔M(P25,P75),支〕 | |||||||||
低危 | 中危 | 高危 | 首次VIS | 24 h VIS | 72 h VIS | 桡动脉 | 股动脉 | ||||||
IABP组 | 33(50.8) | 24(36.9) | 8(12.3) | 5.00(1.17,16.25) | 10.56(2.50,30.00) | 5.33(3.17,10.41) | 51(78.5) | 14(21.5) | 3(2,3) | ||||
IABP+ECMO组 | 9(34.6) | 14(53.8) | 3(11.5) | 7.05(3.53,35.10) | 52.04(11.37,179.25) | 3.93(1.50,10.57) | 21(80.8) | 5(19.2) | 3(1,3) | ||||
检验统计量值 | 1.950a | 2.187a | 0.010a | -1.592 | -4.298 | -1.126 | 0.060a | 0.060a | -0.933 | ||||
P值 | 0.163 | 0.139 | 0.919 | 0.111 | <0.001 | 0.260 | 0.807 | 0.807 | 0.351 | ||||
组别 | 病变血管比例〔n(%)〕 | 梗死相关血管〔n(%)〕 | 植入支架〔n( %)〕 | 急诊PCI〔n( %)〕 | PCI后TIMI血流3级〔n(%)〕 | ||||||||
1支 | 2支 | 3支 | 前降支冠状动脉 | 回旋支冠状动脉 | 左主干冠状动脉 | 右冠状动脉 | |||||||
IABP组 | 8(12.3) | 16(24.6) | 41(63.1) | 41(63.1) | 24(36.9) | 25(38.5) | 7(10.8) | 55(84.6) | 42(64.6) | 57(87.7) | |||
IABP+ECMO组 | 7(26.9) | 5(19.2) | 14(53.8) | 18(69.2) | 12(46.2) | 15(57.7) | 4(15.4) | 21(80.8) | 19(73.1) | 24(92.3) | |||
检验统计量值 | 2.882a | 0.303a | 0.662a | 0.308a | 0.662a | 2.788a | 0.372a | 0.200a | 0.602a | 0.404a | |||
P值 | 0.090 | 0.582 | 0.416 | 0.579 | 0.416 | 0.095 | 0.542 | 0.655 | 0.438 | 0.525 |
Table 1 Comparison of clinical data between the two groups
组别 | 例数 | 男性〔n( %)〕 | 年龄( | IABP后心搏骤停〔n( %)〕 | AMI类型〔n(%)〕 | 吸烟史〔n( %)〕 | 高血压史〔n( %)〕 | 高脂血症史〔n(%)〕 | 糖尿病史〔n( %)〕 | 中度以上肾功能不全史〔n(%)〕 | 心肌梗死史〔n(%)〕 | 脑卒中史〔n( %)〕 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
STEMI | NSTEMI | ||||||||||||
IABP组 | 65 | 35(53.8) | 64.9±11.3 | 11(16.9) | 51(78.5) | 14(21.5) | 18(27.7) | 29(44.6) | 7(10.8) | 26(40.0) | 24(36.9) | 9(13.8) | 15(23.1) |
IABP+ECMO组 | 26 | 16(61.5) | 57.2±14.0 | 15(57.7) | 22(84.6) | 4(15.4) | 12(46.2) | 11(42.3) | 2(7.7) | 8(30.8) | 11(42.3) | 3(11.5) | 4(15.4) |
检验统计量值 | 0.466a | -2.713b | 15.125a | 0.443a | 0.443a | 2.864a | 0.040a | 0.197a | 0.676a | 0.228a | 0.086a | 0.665a | |
P值 | 0.504 | 0.008 | <0.001 | 0.506 | 0.506 | 0.091 | 0.841 | 0.657 | 0.411 | 0.633 | 0.769 | 0.415 | |
组别 | IABP上机前LVEF( | 首次血糖〔M(P25,P75),mmol/l〕 | ALT〔M(P25,P75),u/l〕 | Scr〔M(P25,P75),μmmol/l〕 | 估算肾小球滤过率〔M(P25,P75),%〕 | 糖化血红蛋白〔M(P25,P75),%〕 | NT-proBNP〔M(P25,P75),ng/L〕 | IABP-SHOCKII评分〔M(P25,P75),分〕 | |||||
IABP组 | 42.12±11.73 | 13.10(9.20,17.15) | 91.00(35.50,239.50) | 104.00(72.50,136.85) | 67.94(42.81,94.80) | 6.10(5.70,7.67) | 5 118.00(2 415.50,9 406.00) | 2.00(1.00,3.00) | |||||
IABP+ECMO组 | 42.43±9.13 | 13.95(10.48,18.08) | 99.50(44.00,222.25) | 104.00(87.53,166.05) | 71.29(44.69,93.23) | 6.20(5.78,7.13) | 3 821.50(1 940.00,14 337.30) | 3.00(2.00,3.30) | |||||
检验统计量值 | -0.137b | -0.514 | -0.624 | -1.147 | -0.079b | -0.281 | -0.325 | -0.939 | |||||
P值 | 0.891 | 0.607 | 0.533 | 0.252 | 0.937 | 0.778 | 0.745 | 0.348 | |||||
组别 | IABP-SHOCKⅡ评分〔n(%)〕 | VIS〔M(P25,P75),分〕 | 手术入路〔n(%)〕 | 病变血管数量〔M(P25,P75),支〕 | |||||||||
低危 | 中危 | 高危 | 首次VIS | 24 h VIS | 72 h VIS | 桡动脉 | 股动脉 | ||||||
IABP组 | 33(50.8) | 24(36.9) | 8(12.3) | 5.00(1.17,16.25) | 10.56(2.50,30.00) | 5.33(3.17,10.41) | 51(78.5) | 14(21.5) | 3(2,3) | ||||
IABP+ECMO组 | 9(34.6) | 14(53.8) | 3(11.5) | 7.05(3.53,35.10) | 52.04(11.37,179.25) | 3.93(1.50,10.57) | 21(80.8) | 5(19.2) | 3(1,3) | ||||
检验统计量值 | 1.950a | 2.187a | 0.010a | -1.592 | -4.298 | -1.126 | 0.060a | 0.060a | -0.933 | ||||
P值 | 0.163 | 0.139 | 0.919 | 0.111 | <0.001 | 0.260 | 0.807 | 0.807 | 0.351 | ||||
组别 | 病变血管比例〔n(%)〕 | 梗死相关血管〔n(%)〕 | 植入支架〔n( %)〕 | 急诊PCI〔n( %)〕 | PCI后TIMI血流3级〔n(%)〕 | ||||||||
1支 | 2支 | 3支 | 前降支冠状动脉 | 回旋支冠状动脉 | 左主干冠状动脉 | 右冠状动脉 | |||||||
IABP组 | 8(12.3) | 16(24.6) | 41(63.1) | 41(63.1) | 24(36.9) | 25(38.5) | 7(10.8) | 55(84.6) | 42(64.6) | 57(87.7) | |||
IABP+ECMO组 | 7(26.9) | 5(19.2) | 14(53.8) | 18(69.2) | 12(46.2) | 15(57.7) | 4(15.4) | 21(80.8) | 19(73.1) | 24(92.3) | |||
检验统计量值 | 2.882a | 0.303a | 0.662a | 0.308a | 0.662a | 2.788a | 0.372a | 0.200a | 0.602a | 0.404a | |||
P值 | 0.090 | 0.582 | 0.416 | 0.579 | 0.416 | 0.095 | 0.542 | 0.655 | 0.438 | 0.525 |
组别 | 例数 | 强心药〔n(%)〕 | 血管活性药〔n(%)〕 | CRRT〔n( %)〕 | |||||
---|---|---|---|---|---|---|---|---|---|
西地兰 | 米力农 | 多巴酚丁胺 | 左西孟旦 | 多巴胺 | 肾上腺素 | 去甲肾上腺素 | |||
IABP组 | 65 | 37(56.9) | 31(47.7) | 44(67.7) | 17(26.2) | 55(84.6) | 22(33.8) | 37(56.9) | 6(9.2) |
IABP+ECMO组 | 26 | 16(61.5) | 9(34.6) | 17(65.4) | 11(42.3) | 22(84.6) | 18(69.2) | 24(92.3) | 9(34.6) |
χ2(Z)值 | 0.163 | 1.289 | 0.045 | 2.275 | 0 | 9.439 | 10.522 | 8.693 | |
P值 | 0.687 | 0.256 | 0.832 | 0.131 | 1.000 | 0.002 | <0.001 | 0.003 | |
组别 | 气管插管〔n(%)〕 | 无创呼吸机〔n(%)〕 | 临时起搏器〔n(%)〕 | IABP应用时间〔M(P25,P75),h〕 | CCU住院时间〔M(P25,P75),d〕 | 总住院时间〔M(P25,P75),d〕 | |||
IABP组 | 18(27.7) | 32(49.2) | 3(4.6) | 78.0(47.0,120.0) | 6.0(4.5,10.0) | 13.0(8.0,17.5) | |||
IABP+ECMO组 | 25(96.2) | 12(46.2) | 3(11.5) | 92.0(48.0,147.3) | 10.0(5.50,17.0) | 16.5(9.0,32.0) | |||
χ2(Z)值 | 34.923 | 0.070 | 1.445 | -0.876a | -2.283a | -1.618a | |||
P值 | <0.001 | 0.791 | 0.229 | 0.260 | 0.022 | 0.106 |
Table 2 Comparison of treatment between the two groups
组别 | 例数 | 强心药〔n(%)〕 | 血管活性药〔n(%)〕 | CRRT〔n( %)〕 | |||||
---|---|---|---|---|---|---|---|---|---|
西地兰 | 米力农 | 多巴酚丁胺 | 左西孟旦 | 多巴胺 | 肾上腺素 | 去甲肾上腺素 | |||
IABP组 | 65 | 37(56.9) | 31(47.7) | 44(67.7) | 17(26.2) | 55(84.6) | 22(33.8) | 37(56.9) | 6(9.2) |
IABP+ECMO组 | 26 | 16(61.5) | 9(34.6) | 17(65.4) | 11(42.3) | 22(84.6) | 18(69.2) | 24(92.3) | 9(34.6) |
χ2(Z)值 | 0.163 | 1.289 | 0.045 | 2.275 | 0 | 9.439 | 10.522 | 8.693 | |
P值 | 0.687 | 0.256 | 0.832 | 0.131 | 1.000 | 0.002 | <0.001 | 0.003 | |
组别 | 气管插管〔n(%)〕 | 无创呼吸机〔n(%)〕 | 临时起搏器〔n(%)〕 | IABP应用时间〔M(P25,P75),h〕 | CCU住院时间〔M(P25,P75),d〕 | 总住院时间〔M(P25,P75),d〕 | |||
IABP组 | 18(27.7) | 32(49.2) | 3(4.6) | 78.0(47.0,120.0) | 6.0(4.5,10.0) | 13.0(8.0,17.5) | |||
IABP+ECMO组 | 25(96.2) | 12(46.2) | 3(11.5) | 92.0(48.0,147.3) | 10.0(5.50,17.0) | 16.5(9.0,32.0) | |||
χ2(Z)值 | 34.923 | 0.070 | 1.445 | -0.876a | -2.283a | -1.618a | |||
P值 | <0.001 | 0.791 | 0.229 | 0.260 | 0.022 | 0.106 |
组别 | 例数 | 肺部感染 | 下肢缺血 | 新发脑血管意外事件 | 新发心房颤动 | 急性肾损伤 | 消化道出血 | 住院期间死亡率 | 30 d内死亡率 |
---|---|---|---|---|---|---|---|---|---|
IABP组 | 65 | 4(6.2) | 3(4.6) | 3(4.6) | 2(3.1) | 25(38.5) | 2(3.1) | 24(36.9) | 23(35.4) |
IABP+ECMO组 | 26 | 8(30.8) | 6(23.1) | 2(7.7) | 2(7.7) | 17(65.4) | 7(26.9) | 11(42.3) | 9(34.6) |
χ2值 | 7.797 | 5.182 | 0.339 | 0.941 | 5.417 | 11.850 | 0.228 | 0.005 | |
P值 | 0.005 | 0.023 | 0.561 | 0.332 | 0.020 | 0.001 | 0.633 | 0.945 |
Table 3 Comparison of complications and outcome events between two groups
组别 | 例数 | 肺部感染 | 下肢缺血 | 新发脑血管意外事件 | 新发心房颤动 | 急性肾损伤 | 消化道出血 | 住院期间死亡率 | 30 d内死亡率 |
---|---|---|---|---|---|---|---|---|---|
IABP组 | 65 | 4(6.2) | 3(4.6) | 3(4.6) | 2(3.1) | 25(38.5) | 2(3.1) | 24(36.9) | 23(35.4) |
IABP+ECMO组 | 26 | 8(30.8) | 6(23.1) | 2(7.7) | 2(7.7) | 17(65.4) | 7(26.9) | 11(42.3) | 9(34.6) |
χ2值 | 7.797 | 5.182 | 0.339 | 0.941 | 5.417 | 11.850 | 0.228 | 0.005 | |
P值 | 0.005 | 0.023 | 0.561 | 0.332 | 0.020 | 0.001 | 0.633 | 0.945 |
组别 | 例数 | 收缩压(mm Hg) | 舒张压(mm Hg) | ||||||
---|---|---|---|---|---|---|---|---|---|
上机前 | 治疗后24 h | 治疗后72 h | 上机前 | 治疗后24 h | 治疗后72 h | ||||
IABP组 | 65 | 92±14 | 109±15b | 112±13bc | 57±12 | 64±12b | 65±9b | ||
IABP+ECMO组 | 26 | 93±14 | 111±10b | 120±13abc | 61±13 | 60±10 | 63±13 | ||
F值 | F时间=61.158,F交互=1.904,F组别=2.567 | F时间=3.826,F交互=2.348,F组别=0.047 | |||||||
P值 | P时间<0.001,P交互=0.155,P组别=0.113 | P时间=0.026,P交互=0.102,P组别=0.830 | |||||||
组别 | 心率(次/min) | 乳酸(μmol/L) | pH值 | ||||||
上机前 | 治疗后24 h | 治疗后72 h | 上机前 | 治疗后24 h | 治疗后72 h | 上机前 | 治疗后24 h | 治疗后72 h | |
IABP组 | 98±26 | 109±15 | 96±20 | 4.71±3.32 | 2.24±1.73b | 1.17±0.68bc | 7.33±0.15 | 7.38±0.15b | 7.46±0.65bc |
IABP+ECMO组 | 89±29 | 93±20 | 89±23 | 5.24±2.41 | 1.28±0.39ab | 1.20±0.36bc | 7.29±0.14 | 7.45±0.09ab | 7.47±0.07bc |
F值 | F时间=0.631,F交互=0.553,F组别=2.135 | F时间=60.551,F交互=7.959,F组别=0.220 | F时间=42.867,F交互=12.333,F组别=0.057 | ||||||
P值 | P时间=0.535,P交互=0.577,P组别=0.147 | P时间<0.001,P交互=0.001,P组别=0.640 | P时间<0.001,P交互<0.001,P组别=0.811 |
Table 4 Comparison of the hemodynamic indexes between two groups
组别 | 例数 | 收缩压(mm Hg) | 舒张压(mm Hg) | ||||||
---|---|---|---|---|---|---|---|---|---|
上机前 | 治疗后24 h | 治疗后72 h | 上机前 | 治疗后24 h | 治疗后72 h | ||||
IABP组 | 65 | 92±14 | 109±15b | 112±13bc | 57±12 | 64±12b | 65±9b | ||
IABP+ECMO组 | 26 | 93±14 | 111±10b | 120±13abc | 61±13 | 60±10 | 63±13 | ||
F值 | F时间=61.158,F交互=1.904,F组别=2.567 | F时间=3.826,F交互=2.348,F组别=0.047 | |||||||
P值 | P时间<0.001,P交互=0.155,P组别=0.113 | P时间=0.026,P交互=0.102,P组别=0.830 | |||||||
组别 | 心率(次/min) | 乳酸(μmol/L) | pH值 | ||||||
上机前 | 治疗后24 h | 治疗后72 h | 上机前 | 治疗后24 h | 治疗后72 h | 上机前 | 治疗后24 h | 治疗后72 h | |
IABP组 | 98±26 | 109±15 | 96±20 | 4.71±3.32 | 2.24±1.73b | 1.17±0.68bc | 7.33±0.15 | 7.38±0.15b | 7.46±0.65bc |
IABP+ECMO组 | 89±29 | 93±20 | 89±23 | 5.24±2.41 | 1.28±0.39ab | 1.20±0.36bc | 7.29±0.14 | 7.45±0.09ab | 7.47±0.07bc |
F值 | F时间=0.631,F交互=0.553,F组别=2.135 | F时间=60.551,F交互=7.959,F组别=0.220 | F时间=42.867,F交互=12.333,F组别=0.057 | ||||||
P值 | P时间=0.535,P交互=0.577,P组别=0.147 | P时间<0.001,P交互=0.001,P组别=0.640 | P时间<0.001,P交互<0.001,P组别=0.811 |
组别 | 例数 | 出院1个月 | 出院3个月 | 出院6个月 | 出院12个月 |
---|---|---|---|---|---|
IABP组 | 65 | 41(63.1) | 32(49.2) | 20(30.8) | 17(26.2) |
IABP+ECMO组 | 26 | 15(57.7) | 14(53.8) | 13(50.0) | 13(50.0) |
χ2值 | 0.228 | 0.158 | 2.972 | 4.779 | |
P值 | 0.633 | 0.691 | 0.085 | 0.029 |
Table 5 Survival rate during follow-up in the two groups
组别 | 例数 | 出院1个月 | 出院3个月 | 出院6个月 | 出院12个月 |
---|---|---|---|---|---|
IABP组 | 65 | 41(63.1) | 32(49.2) | 20(30.8) | 17(26.2) |
IABP+ECMO组 | 26 | 15(57.7) | 14(53.8) | 13(50.0) | 13(50.0) |
χ2值 | 0.228 | 0.158 | 2.972 | 4.779 | |
P值 | 0.633 | 0.691 | 0.085 | 0.029 |
变量 | β | SE | Wald χ2值 | OR(95%CI) | P值 |
---|---|---|---|---|---|
IABP-SHOCKⅡ评分 | 0.116 | 0.151 | 0.595 | 1.123(0.836,1.509) | 0.440 |
吸烟史 | 0.806 | 0.481 | 2.802 | 2.238(0.871,5.748) | 0.094 |
高血压史 | -0.094 | 0.469 | 0.040 | 0.910(0.363,2.282) | 0.841 |
糖尿病史 | -0.405 | 0.495 | 0.672 | 0.667(0.253,1.758) | 0.412 |
高脂血症史 | -0.370 | 0.838 | 0.195 | 0.69(0.134,3.566) | 0.658 |
中度以上肾功能不全史 | 0.225 | 0.473 | 0.227 | 1.253(0.496,3.165) | 0.634 |
心肌梗死史 | -0.209 | 0.711 | 0.086 | 0.812(0.201,3.271) | 0.769 |
脑卒中史 | -0.501 | 0.618 | 0.656 | 0.606(0.180,2.036) | 0.418 |
IABP后心搏骤停 | 1.901 | 0.517 | 13.538 | 6.694(2.431,18.430) | <0.001 |
年龄 | -0.052 | 0.021 | 6.436 | 0.959(0.912,0.988) | 0.011 |
治疗后24 h VIS | 0.023 | 0.007 | 12.503 | 1.024(1.010,1.037) | <0.001 |
CRRT | 1.650 | 0.595 | 7.698 | 5.206(1.623,16.696) | 0.006 |
乳酸(治疗后24 h) | -1.826 | 0.587 | 9.693 | 0.161(0.051,0.508) | 0.002 |
肾上腺素 | 1.481 | 0.499 | 8.800 | 4.398(1.653,11.700) | 0.003 |
去甲肾上腺素 | 2.206 | 0.777 | 8.053 | 9.081(1.979,41.677) | 0.005 |
Table 6 Univariate logistic regression analysis to predict the need for ECMO support in patients with AMI combined with CS and IABP
变量 | β | SE | Wald χ2值 | OR(95%CI) | P值 |
---|---|---|---|---|---|
IABP-SHOCKⅡ评分 | 0.116 | 0.151 | 0.595 | 1.123(0.836,1.509) | 0.440 |
吸烟史 | 0.806 | 0.481 | 2.802 | 2.238(0.871,5.748) | 0.094 |
高血压史 | -0.094 | 0.469 | 0.040 | 0.910(0.363,2.282) | 0.841 |
糖尿病史 | -0.405 | 0.495 | 0.672 | 0.667(0.253,1.758) | 0.412 |
高脂血症史 | -0.370 | 0.838 | 0.195 | 0.69(0.134,3.566) | 0.658 |
中度以上肾功能不全史 | 0.225 | 0.473 | 0.227 | 1.253(0.496,3.165) | 0.634 |
心肌梗死史 | -0.209 | 0.711 | 0.086 | 0.812(0.201,3.271) | 0.769 |
脑卒中史 | -0.501 | 0.618 | 0.656 | 0.606(0.180,2.036) | 0.418 |
IABP后心搏骤停 | 1.901 | 0.517 | 13.538 | 6.694(2.431,18.430) | <0.001 |
年龄 | -0.052 | 0.021 | 6.436 | 0.959(0.912,0.988) | 0.011 |
治疗后24 h VIS | 0.023 | 0.007 | 12.503 | 1.024(1.010,1.037) | <0.001 |
CRRT | 1.650 | 0.595 | 7.698 | 5.206(1.623,16.696) | 0.006 |
乳酸(治疗后24 h) | -1.826 | 0.587 | 9.693 | 0.161(0.051,0.508) | 0.002 |
肾上腺素 | 1.481 | 0.499 | 8.800 | 4.398(1.653,11.700) | 0.003 |
去甲肾上腺素 | 2.206 | 0.777 | 8.053 | 9.081(1.979,41.677) | 0.005 |
变量 | β | SE | Wald χ2值 | OR(95%CI) | P值 |
---|---|---|---|---|---|
IABP后心搏骤停 | 2.780 | 1.038 | 7.174 | 16.114(2.108,123.197) | 0.007 |
年龄 | -0.075 | 0.036 | 4.386 | 0.928(0.865,0.995) | 0.036 |
治疗后24 h VIS | 0.023 | 0.009 | 7.085 | 1.023(1.006,1.041) | 0.008 |
CRRT | 1.834 | 1.091 | 2.826 | 6.256(0.738,53.060) | 0.093 |
乳酸(治疗后24 h) | -1.814 | 0.982 | 3.415 | 0.163(0.024,1.116) | 0.065 |
肾上腺素 | 0.332 | 0.845 | 0.155 | 1.394(0.266,7.307) | 0.694 |
去甲肾上腺素 | 1.265 | 1.018 | 1.543 | 3.543(0.482,26.074) | 0.214 |
Table 7 Multivariate Logistic regression analysis to predict the need for ECMO support in patients with AMI combined with CS and IABP
变量 | β | SE | Wald χ2值 | OR(95%CI) | P值 |
---|---|---|---|---|---|
IABP后心搏骤停 | 2.780 | 1.038 | 7.174 | 16.114(2.108,123.197) | 0.007 |
年龄 | -0.075 | 0.036 | 4.386 | 0.928(0.865,0.995) | 0.036 |
治疗后24 h VIS | 0.023 | 0.009 | 7.085 | 1.023(1.006,1.041) | 0.008 |
CRRT | 1.834 | 1.091 | 2.826 | 6.256(0.738,53.060) | 0.093 |
乳酸(治疗后24 h) | -1.814 | 0.982 | 3.415 | 0.163(0.024,1.116) | 0.065 |
肾上腺素 | 0.332 | 0.845 | 0.155 | 1.394(0.266,7.307) | 0.694 |
去甲肾上腺素 | 1.265 | 1.018 | 1.543 | 3.543(0.482,26.074) | 0.214 |
[1] |
中国医师协会心力衰竭专业委员会,国家心血管病专家委员会心力衰竭专业委员会,中华心力衰竭和心肌病杂志编辑委员会. 经皮机械循环辅助临床应用及管理中国专家共识[J].中华心力衰竭和心肌病杂志,2020,4(3):145-158.
|
[2] |
中国心胸血管麻醉学会,中华医学会麻醉学分会,中国医师协会麻醉学医师分会,等. 不同情况下成人体外膜肺氧合临床应用专家共识(2020版)[J]. 中国循环杂志,2020,35(11):1052-1063. DOI:10.3969/j.issn.1000-3614.2020.11.002.
|
[3] |
中华医学会心血管病学分会心血管急重症学组,中华心血管病杂志编辑委员会. 心原性休克诊断和治疗中国专家共识(2018)[J].中华心血管病杂志,2019,47(4):265-277.
|
[4] |
中华医学会心血管病学分会,中华心血管病杂志编辑委员会.急性ST段抬高型心肌梗死诊断和治疗指南(2019)[J].中华心血管病杂志,2019,47(10):766-783.
|
[5] |
曹佳宁,刘文娴,陈立颖,等. IABP-SHOCKⅡ评分对伴发心源性休克的ST段抬高型心肌梗死患者住院死亡的预测价值[J].中华急诊医学杂志,2018,27(11):1260-1264.
|
[6] |
|
[7] |
|
[8] |
|
[9] |
|
[10] |
|
[11] |
|
[12] |
|
[13] |
|
[14] |
|
[15] |
|
[16] |
|
[17] |
|
[18] |
|
[19] |
|
[20] |
|
[21] |
|
[22] |
|
[23] |
|
[24] |
|
[25] |
|
[1] | YU Xinyan, ZHAO Jun, ZHAO Xiaoye, JIANG Qingru, CHEN Yatian, WANG Yan, ZHANG Haicheng. Application of Mobile Smart Healthcare in the Prevention and Control of Cardiovascular Diseases in Elderly Patients with Chronic Diseases in Primary Care [J]. Chinese General Practice, 2023, 26(33): 4167-4172. |
[2] | WANG Yu, CHEN Yan, HAN Yuanyuan, XU Qing, CHEN Shengyue, LYU Zhibo, LU Chuan, ZHENG Mingxin, ZHAO Xin. Platelet-lymphocyte Ratio Predicts In-hospital Mortality in Elderly Patients with Acute Myocardial Infarction [J]. Chinese General Practice, 2023, 26(33): 4137-4142. |
[3] | PAN Yaojia, WANG Weiqiang, YI Weizhuo, GAO Bing, FU Fanglin, HAN Zheng, SUN Meng, DONG Yaqin, GU Huaicong. Relationship between Triglyceride-glucose Index and Risk of Cardiovascular Diseases in Middle-aged Obese Residents of Different Genders [J]. Chinese General Practice, 2023, 26(29): 3628-3635. |
[4] | WANG Zhen, SHEN Guoqi, LI Yanan, ZHU Yinghua, QIU Hang, ZHENG Di, XU Tongda, LI Wenhua. Development and Validation of a Risk Prediction Model for Contrast-induced Acute Kidney Injury after Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction [J]. Chinese General Practice, 2023, 26(29): 3650-3656. |
[5] | MIAO Guangrui, PANG Shuo, ZHOU Yuanhang, DUAN Mingxuan, BAI Linpeng, ZHANG Qingyang, ZHAO Xiaoyan, DONG Jianzeng. Short-term Prognostic Value of Early Fluid Balance and Lactate Clearance in Patients with Acute Myocardial Infarction Combined with Cardiogenic Shock Treated with Extracorporeal Membrane Oxygenation [J]. Chinese General Practice, 2023, 26(27): 3397-3402. |
[6] | CHEN Yan, CHEN Shengyue, HAN Yuanyuan, LYU Zhibo, XU Qing, ZHAO Xin. Combined Predictive Value of Neutrophil-to-lymphocyte Ratio and Platelet-to-lymphocyte Ratio for In-hospital Mortality Risk in Patients with Acute Myocardial Infarction [J]. Chinese General Practice, 2023, 26(20): 2482-2487. |
[7] | YUE Bocheng, HOU Qiqi, HAN Quanle, YANG Bo, WU Zheng, WU Jianmei, CHEN Shuohua, WU Shouling, LI Kangbo. Effect of Atrial Fibrillation on the Risk of New-onset Myocardial Infarction in Hypertensive Population [J]. Chinese General Practice, 2023, 26(14): 1739-1744. |
[8] | LIU Chuanfen, LI Zheng, WU Manyan, CUI Yuxia, SONG Jing, ZHANG Chunying, CHEN Hong. Analysis of Serum Lipid Level and Drug Use in Patients with Acute Myocardial Infarction [J]. Chinese General Practice, 2023, 26(11): 1325-1329. |
[9] | LIU Taotao, LI Tianrong, WANG Xue, CHEN Jiameng, SHUAI Zhiqin, LI Lisheng, XU Shangfu. Nanoparticle- and Exosome-based Targeted Drug Delivery Systems Used in the Diagnosis and Treatment of Atherosclerosis: Opportunities and Challenges [J]. Chinese General Practice, 2023, 26(08): 903-910. |
[10] | DENG Yifan, ZHU Mixue, LIU Juan, NIE Ri, HE Shenghu, ZHANG Jing. Predictive Value of Remnant Lipoprotein-cholesterol and Atherogenic Index of Plasma for First-time Acute Myocardial Infarction in Young Adults [J]. Chinese General Practice, 2023, 26(06): 659-664. |
[11] | ZHANG Haicheng, YU Xinyan, WANG Hongyu, XUE Tao, LIAO Xiaoyang, FAN Yongmei, ZHANG Qinghong. Discussion on the Difficulties and Bottlenecks in the Management of Remote ECG-based Screening for Cardiovascular Disease Risk in Hierarchical Diagnosis and Treatment [J]. Chinese General Practice, 2023, 26(05): 525-531. |
[12] | WU Changyong, BAO Suli, XU Fei, PENG Yunzhu. Latest Advances in Exercise-induced Autophagy in Improving Cardiovascular Disease Prognosis [J]. Chinese General Practice, 2023, 26(05): 629-634. |
[13] | WANG Zhe, ZHAO Haibin, WANG Guoliang, MA Xiaojuan, YIN Huijun. Complete Revascularization for Acute Myocardial Infarction and Multivessel Disease: an Overview of Systematic Reviews [J]. Chinese General Practice, 2023, 26(02): 142-153. |
[14] | TANG Zhaoyun, HE Yang, CHEN Cong, YANG Xiaodan, WU Xinhua, LIU Hong. Risk Assessment of Ischemic Cardiovascular Disease in Rural Naxi Population in Low-to-high Altitudes [J]. Chinese General Practice, 2022, 25(36): 4522-4527. |
[15] | SUN Zhenzhen, LIU Huanhuan, CHEN Kaining, LOU Qingqing. New Advances in the Value of the Normal Urinary Albumin as a Predictor of Multiple Diseases [J]. Chinese General Practice, 2022, 25(33): 4191-4195. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||